摘要
目的探究Beclin1、缺氧诱导因子-1α(hypoxia inducible factor-1α,HIF-1α)表达水平与曲妥珠单抗治疗人表皮生长因子受体2(human epidermal growth factor receptor 2,HER2)阳性乳腺癌的疗效关系。方法收集2021年3月至2023年5月山东大学齐鲁医院经手术治疗后行曲妥珠单抗治疗的90例HER2阳性乳腺癌患者的临床资料。采用免疫组化法测定全部患者Beclin1、HIF-1α表达水平。按化疗疗效将患者分为有效组与无效组,比较两组临床资料及Beclin1、HIF-1α表达水平,采用Logistic回归分析评估Beclin1、HIF-1α表达水平与患者疗效的关系。结果90例HER2阳性乳腺癌患者经曲妥珠单抗治疗后,有效率72.22%(65/90),无效率27.78%(25/90)。HER2阳性乳腺癌患者治疗后Beclin1不表达、低表达、高表达分别为11例、26例、53例,优于治疗前的23例、29例、38例;HIF-1α不表达、低表达、高表达分别为53例、8例、29例,优于治疗前的32例、17例、41例(Z=6.50、7.31,P<0.05)。有效组患者TNM分期Ⅰ~Ⅱ期、组织学分级3级的占比83.08%(54/65)、87.69%(57/65)比无效组的60.00%(15/25)、64.00%(16/25)高(χ^(2)=5.38、6.62,P<0.05)。有效组患者治疗前Beclin1高表达的占比53.85%(35/65)比无效组12.00%(3/25)高,HIF-1α高表达的占比36.92%(24/65)比无效组68.00%(17/25)低(Z=16.76、7.59,P<0.05)。Logistic回归分析结果显示,TNM分期、组织学分级、Beclin1表达水平及HIF-1α表达水平均为影响HER2阳性乳腺癌患者疗效的相关因素(P<0.05)。结论Beclin1、HIF-1α表达水平与曲妥珠单抗治疗HER2阳性乳腺癌的疗效有关,可作为患者疗效的预测指标。
Objective To explore the relationship between the expression levels of beclin1,hypoxia-induced-factor-1α(HIF-1α)and the efficacy of trastuzumab on human epidermal growth factor receptor 2(HER2)positive breast cancer.Methods Clinical data of 90 patients with HER2-positive breast cancer treated with trastuzumab after surgery in our hospital from Mar.2021 to May.2023 were collected.The expression levels of Beclin1 and HIF-1αin all patients were determined by immunohistochemistry.Patients were divided into the effective group and the ineffective group according to chemotherapy efficacy.Clinical data and expression levels of Beclin1 and HIF-1αwere compared between the two groups,and the relationship between expression levels of Beclin1,HIF-1αand the efficacy was evaluated by Logistic regression analysis.ResultsIn 90 patients with HER2-positive breast cancer treated with trastuzumab,the effective rate was 72.22%(65/90)and the ineffective rate was 27.78%(25/90).Beclin1 had no expression,low expression and high expression in 11,26 and 53 HER2-positive breast cancer patients after treatment,which were better than the 23,29 and 38 cases before treatment;HIF-1αhad no expression in 53 cases,low expression in 8 cases and high expression in 29 cases,which was better than that before treatment in 32 cases,17 cases and 41 cases(Z=6.50,7.31,P<0.05).The proportion of TNM stages I-II and histological grade 3 in the effective group was 83.08%(54/65)and 87.69%(57/65),higher than that in the ineffective group[60.00%(15/25)and 64.00%(16/25)(χ^(2)=5.38,6.62,P<0.05)].The high expression of Beclin1 in the effective group was higher[53.85%(35/65)vs.12.00%(3/25)],and the high expression of HIF-1αwas lower[36.92%(24/65)vs.68.00%(17/25)](Z=16.76,7.59,P<0.05).Logistic regression analysis showed that TNM stage,histological grade,Beclin1 expression level and HIF-1αexpression level were all related factors affecting the curative effect of HER2-positive breast cancer patients(P<0.05).ConclusionsBeclin1 and HIF-1αexpression levels are rel
作者
李雯
吴庆和
李宁
Li Wen;Wu Qinghe;Li Ning(Department of Pharmacy,Qilu Hospital,Shandong University,Qingdao 266035,China;Western Pharmacy,Qilu Hospital,Shandong University,Qingdao 266035,China)
出处
《中华内分泌外科杂志（中英文）》
CAS
2024年第5期624-628,共5页
Chinese Journal of Endocrine Surgery
基金
山东省科技发展计划(2013GGE27052)。
